Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 25, 2026

Can Kevin Warsh Tighten Policy Without Crossing Trump?

View original at finance.yahoo.com
Can Kevin Warsh Tighten Policy Without Crossing Trump?…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump publicly told Warsh to be totally independent and just do a great job.

    60% confidence
  • The 4% unemployment rate provides political cover for the Federal Reserve to pursue aggressive monetary tightening.

    60% confidence
  • The CNBC Fast Money panel consensus is that there are now completely equal odds of either a rate hike or a rate cut as the Federal Reserve's next strategic policy move.

    60% confidence
  • The CNBC panel concluded that Warsh's path of least resistance for tightening is quantitative tightening of the balance sheet rather than hiking the federal funds rate, because QT is technical, slow-moving, and rarely makes the evening news.

    60% confidence
  • The macroeconomic case for resuming aggressive central bank balance sheet runoff is becoming incredibly straightforward for market participants, given Core PCE at the 91st percentile of its trailing twelve-month range.

    60% confidence
  • A significant disconnect exists between complacent options markets and distressed consumer sentiment, creating risk for investors.

    60% confidence
  • JPMorgan's chief economist warned that the Goldilocks economic period is officially ending, signaling a structural shift in monetary conditions.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com